Efficacy and tolerability of the dietary supplement “Altsinara” in subjects with hypercholesterolemia: a laboratory component of the clinical study
DOI:
https://doi.org/10.24959/cphj.18.1479Keywords:
dietary supplement “Altsinara”, hypercholesterolemia, efficiency, tolerability, laboratory studiesAbstract
The importance of dyslipidemia as one of the main risk factors of cardiovascular disease is currently undoubted. Medicines of plant origin with the anti-atherogenic potential are of particular relevance for prevention of the dyslipidemia development of borderline states.
Aim. To study the laboratory component of the efficacy and tolerability of the dietary supplement “Altsinara”, produced by PJSC SIC “Borshchahivskiy CPP” compared to placebo in subjects with hypercholesterolemia in the framework of the clinical study “Randomized, simple blind, placebo-controlled study of the efficacy and tolerability of dietary supplement “Altsinara” produced by PJSC SIC “Borshchahivskiy CPP” with the participation of volunteers with hypercholesterolemia”.
Materials and methods. The study was conducted with the participation of 60 volunteers with hypercholesterolemia, whose average age was 48.83 ± 1.17 years. To assess the laboratory component of the effectiveness and tolerability of the dietary supplement “Altsinara” the indicators of the clinical and biochemical blood test were used for 1 (screening), 3 (day 45) and 4 (final day 90) visit.
Results. The prevailing efficacy and good tolerability of long-term use (within 90 days) of a dietary supplement “Altsinara”, tablets produced by PJSC SIC “Borshchahivskiy CPP”, Ukraine, have been proven. Based on the results of the test a dietary supplement “Altsinara”, tablets produced by PJSC SIC “Borshchahivskiy CPP”, Ukraine, can be recommended as a special food product for long-term use in persons with hypercholesterolemia and/or persons with a tendency to hypercholesterolemia (aggravated family history, overweight, inappropriate nutrition, etc.).
Conclusions. Based on the results of a randomized, simple blind, placebo-controlled study on the effectiveness and tolerability of the dietary supplement “Altsinara” produced by PJSC SIC “Borshchahivskiy CPP” with the participation of volunteers with hypercholesterolemia its prevailing efficacy and good tolerability in long-term use (within 90 days) have been proven.
References
Serhyenko, O. M., Zhyhunova, A. K. (2013). Ukrainskyi medychnyi chasopys, 1, 77–80.
Harnyk, T. P., Tumanov, V. A., Pokanevych, V. V., Frolov, V. M., Peresadin, M. O. (2012). Fitoterapiia. Chasopys, 1, 4–11.
WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. (2017). World Health Organization, 118.
Kunle, O. F., Egharevba, H. O., Ahmadu, P. O. (2012). Standardization of herbal medicines - A review. International Journal of Biodiversity and Conservation, 4(3), 101–112. https://doi.org/10.5897/ijbc11.163
Tattis, A., Zupanets, I. A., Otrishko, I. A., & Grintsov, I. F. (2015). The study of the safety profile of “Altsinara” drug under the conditions of acute toxicity modeling. Klìnìčna farmacìâ, 19(3), 44–47. https://doi.org/10.24959/cphj.15.1350
Tattis, A., Zupanets, I. A., Shebeko, S. K., Otrishko, I. A., Hrintsov, Ye. F. (2015). Odeskyi medychnyi zhurnal,6 (152), 37–42.
Tattis, A., Zupanets, I. A., Shebeko, S. K., Otrishko, I. A., Grintsov, Ie. F. (2015). Study of lipid-lowering activity of the drug «Altsinarа» in the experiment. The Pharma Innovation Journal, 4 (8), 77–80.
Zupanets, I. A., Tattis, A., Shebeko, S. K., Otrishko, I. A., Hrintsov, Ye. F., Dobrovolnyi, O. O., Fesenko, S. O., Shalamai, A. S., Shylkina, O. O. (2016). Rozrobka efektyvnykh zasobiv hipolipidemichnoi ta antyaterohennoi dii na osnovi ekstraktu artyshoku ta poroshku chasnyku. Informatsiinyi lyst pro novovvedennia v sferi okhorony zdorovia № 194-2016. Ukrmedpatentinform MOZ Ukrainy. Vypusk z problemy «Klinichna farmakolohiia i klinichna farmatsiia», Kyiv, 3.
Nastanova ST-N MOZU 42-7.0:2008 «Likarski zasoby. (2009). Nalezhna klinichna praktyka», 48.
ICH E6: Good Clinical Practice: Consolidated guideline, CPMP/ICH/135/95. (n.d.).
Helsinskaya deklaratsiya Vsemirnoy meditsinskoy assotsiatsii. Eticheskie printsipyi provedeniya meditsinskih issledovaniy s uchastiem cheloveka v kachestve sub'ekta (2013).
Lapach, S. N., Chubenko, A. V., Babych, P. N. (2002). Osnovnye printcipy primeneniia statisticheskikh metodov v klinicheskikh ispytaniiakh. Kyiv: MORION, 160.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
